Hosted on MSN

Cabaletta Bio Reports Promising Data from RESET Trials for Transformative Autoimmune Therapy

PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) has unveiled new clinical and translational data from its ongoing RESET-Myositis™, RESET-SLE™, and RESET-SSc™ trials. The findings highlight ...
Hosted on MSN

Cabaletta Bio Updates Progress on RESET-Myositis Trial and Regulatory Milestones

PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) has announced key updates on its RESET-Myositis trial and plans for the anticipated 2027 Biologics License Application (BLA) submission for ...